David M. Hyman

Active 2011–2022

139
Papers
45,854
Citations
87
h-index
139
i10-index

Citations

Citations per year for David M. Hyman1992: 3 citations1998: 4 citations1999: 1 citations2000: 2 citations2004: 4 citations2007: 1 citations2009: 2 citations2011: 2 citations2012: 2 citations2013: 4 citations2014: 13 citations2015: 40 citations2016: 112 citations2017: 279 citations2018: 620 citations2019: 2,255 citations2020: 3,501 citations2021: 3,580 citations2022: 2,922 citations2023: 2,146 citations2024: 3,054 citations2025: 1,411 citations2026: 48 citations1993–1997: no citations, so these years are not shown2001–2003: no citations, so these years are not shown2005–2006: no citations, so these years are not shown2008: no citations, so this year is not shown2010: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 6,849 citing papers, 27.7% of this breakdownChina: 2,847 citing papers, 11.5% of this breakdownItaly: 1,418 citing papers, 5.7% of this breakdownUnited Kingdom: 1,393 citing papers, 5.6% of this breakdownGermany: 1,178 citing papers, 4.8% of this breakdownFrance: 1,019 citing papers, 4.1% of this breakdownSpain: 902 citing papers, 3.6% of this breakdownJapan: 878 citing papers, 3.5% of this breakdownCanada: 804 citing papers, 3.3% of this breakdownNetherlands: 642 citing papers, 2.6% of this breakdownAustralia: 597 citing papers, 2.4% of this breakdownSwitzerland: 516 citing papers, 2.1% of this breakdown
0%27.7%Other 23.1%

Fields

  • Medicine60.9%
  • Biochemistry, Genetics and Molecular Biology32.2%
  • Immunology and Microbiology2.1%
  • Computer Science1.3%
  • Engineering1%
  • Chemistry0.5%
  • Other2%

Topics

  • Cancer Genomics and Diagnostics8.1%
  • Lung Cancer Treatments and Mutations4.4%
  • Cancer Immunotherapy and Biomarkers3.9%
  • Genetic factors in colorectal cancer2.4%
  • Colorectal Cancer Treatments and Studies1.8%
  • Pancreatic and Hepatic Oncology Research1.8%
  • Other77.6%

Coauthors

All papers

Open in search
  1. A view on drug resistance in cancer

    Authors: , , - Nature 2019 cited by 2,793

  2. OncoKB: A Precision Oncology Knowledge Base

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Antonio Omuro, Michael A. Postow, Dana E. Rathkopf, Alexander N. Shoushtari, Neerav Shukla, Martin H. Voss, Ederlinda Paraiso, Ahmet Zehir, Michael F. Berger, Barry S. Taylor, Leonard B. Saltz, Gregory J. Riely, Marc Ladanyi, David M. Hyman, José Baselga, Paul Sabbatini, David B. Solit, Nikolaus Schultz - JCO Precision Oncology 2017 cited by 2,698

  3. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Laetitia Borsu, Justyna Sadowska, Jacklyn Casanova, Ruben Bacares, Iwona Kiecka, Anna Razumova, Julie B Son, Lisa Stewart, Tessara Baldi, Kerry Mullaney, Hikmat Al‐Ahmadie, Efsevia Vakiani, Adam Abeshouse, Alexander Penson, Philip Jonsson, Niedzica Camacho, Matthew T. Chang, Helen Won, Benjamin Groß, Ritika Kundra, Zachary Heins, Hsiao‐Wei Chen, Sarah Phillips, Hongxin Zhang, Jiaojiao Wang, Angelica Ochoa, Jonathan Wills, Michael Eubank, Stacy B. Thomas, Stuart M. Gardos, Dalicia N. Reales, Jesse Galle, Robert Durany, Roy Cambria, Wassim Abida, Andrea Cercek, Darren R. Feldman, Mrinal M. Gounder, A. Ari Hakimi, James J. Harding, Gopa Iyer, Yelena Y. Janjigian, Emmet Jordan, Ciara M. Kelly, Maeve A. Lowery, Luc G.T. Morris, Antonio Omuro, Nitya Raj, Pedram Razavi, Alexander N. Shoushtari, Neerav Shukla, Tara E. Soumerai, Anna M. Varghese, Rona Yaeger, Jonathan Coleman, Bernard H. Bochner, Gregory J. Riely, Leonard B. Saltz, Howard I. Scher, Paul Sabbatini, Mark E. Robson, David S. Klimstra, Barry S. Taylor, José Baselga, Nikolaus Schultz, David M. Hyman, Maria E. Arcila, David B. Solit, Marc Ladanyi, Michael F. Berger - Nature Medicine 2017 cited by 3,517

  4. AACR Project GENIE: Powering Precision Medicine through an International Consortium

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Walter Kinyua, Priti Kumari, Ritika Kundra, Marc Ladanyi, Céline Lefèbvre, Michele L. Lenoue-Newton, Eva M. Lepisto, Mia Levy, Neal I. Lindeman, James Lindsay, David Liu, Zhibin Lu, Laura E. MacConaill, Ian Maurer, David S. Maxwell, Gerrit A. Meijer, Funda Meric‐Bernstam, Christine Micheel, Clinton Miller, Gordon B. Mills, Nathanael D. Moore, Petra M. Nederlof, Larsson Omberg, John A. Orechia, Ben Ho Park, Trevor J. Pugh, Brendan Reardon, Barrett J. Rollins, Mark J. Routbort, Charles L. Sawyers, Deborah Schrag, Nikolaus Schultz, Kenna Shaw, Priyanka Shivdasani, Lillian L. Siu, David B. Solit, Gabe S. Sonke, Jean Charles Soria, Parin Sripakdeevong, Natalie Stickle, Thomas Stricker, Shawn M. Sweeney, Barry S. Taylor, Jelle J. ten Hoeve, Stacy B. Thomas, Eliezer M. Van Allen, Laura van ‘t Veer, Tony van de Velde, Harm van Tinteren, Victor E. Velculescu, Carl Virtanen, Emile E. Voest, Lucy Lu Wang, Chetna Wathoo, Stuart Watt, Celeste Yu, Thomas Yu, Emily Yu, Ahmet Zehir, Hongxin Zhang - Cancer Discovery 2017 cited by 2,004

  5. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brian B. Tuch, Kevin Ebata, Scott Cruickshank, Nora Ku, Michael C. Cox, Douglas S. Hawkins, David S. Hong, David M. Hyman - New England Journal of Medicine 2018 cited by 2,728

  6. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 cited by 994

  7. Cancer therapy shapes the fitness landscape of clonal hematopoiesis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Konrad H. Stopsack, Barbara Spitzer, Simon Mantha, James A. Fagin, Laura Boucai, Christopher J. Gibson, Benjamin L. Ebert, Andrew L. Young, Todd E. Druley, Koichi Takahashi, Nancy Gillis, Markus Ball, Eric Padron, David M. Hyman, José Baselga, Larry Norton, Stuart M. Gardos, Virginia M. Klimek, Howard I. Scher, Dean F. Bajorin, Eder Paraiso, Ryma Benayed, Maria E. Arcila, Marc Ladanyi, David B. Solit, Michael F. Berger, Martin S. Tallman, Montserrat García‐Closas, Nilanjan Chatterjee, Luis A. Díaz, Ross L. Levine, Lindsay M. Morton, Ahmet Zehir, Elli Papaemmanuil - Nature Genetics 2020 cited by 741

  8. The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nikolaus Schultz, Mark E. Robson, Clifford A. Hudis, Edi Brogi, Agnès Viale, Larry Norton, Maura N. Dickler, Michael F. Berger, Christine A. Iacobuzio–Donahue, Sarat Chandarlapaty, Maurizio Scaltriti, Jorge S. Reis‐Filho, David B. Solit, Barry S. Taylor, José Baselga - Cancer Cell 2018 cited by 1,006

  9. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes

    Authors: , , , , , , , , , , , , , , - Cell stem cell 2017 cited by 855

  10. Small molecules, big impact: 20 years of targeted therapy in oncology

    Authors: , , , - The Lancet 2020 cited by 602

  11. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations

    Authors: , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 cited by 1,734

  12. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

    Authors: , , , , , , , , , , , , , , , , , , , - Science 2017 cited by 1,185

  13. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alexandra S. Heerdt, Marc Ladanyi, David M. Hyman, David R. Jones, Monica Morrow, Gregory J. Riely, Howard I. Scher, Charles M. Rudin, Mark E. Robson, Luis A. Díaz, David B. Solit, Alexander M. Aravanis, Jorge S. Reis‐Filho - Nature Medicine 2019 cited by 767

  14. Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2018 cited by 864

  15. Genome doubling shapes the evolution and prognosis of advanced cancers

    Authors: , , , , , , , , , , , , , , , , , , , - Nature Genetics 2018 cited by 692

  16. Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies

    Authors: , , , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2018 cited by 592

  17. Mechanisms of Resistance to Noncovalent Bruton’s Tyrosine Kinase Inhibitors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , David M. Hyman, Iannis Aifantis, Anthony Mato, Justin Taylor, Omar Abdel-Wahab - New England Journal of Medicine 2022 cited by 237

  18. HER kinase inhibition in patients with HER2- and HER3-mutant cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alexander Drilon, James J. Harding, Gopa Iyer, Barry S. Taylor, Michael F. Berger, Richard E. Cutler, Feng Xu, Anna Butturini, Lisa D. Eli, Grace Mann, Cynthia Farrell, Alshad S. Lalani, Richard Bryce, Carlos L. Arteaga, Funda Meric‐Bernstam, José Baselga, David B. Solit - Nature 2018 cited by 788

  19. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

    Authors: , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2018 cited by 480

  20. HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Anuja Bhalkikar, Fabiola Cecchi, David M. Hyman, Jason S. Lewis, Darren J. Buonocore, Alan L. Ho, Vicky Makker, Jorge S. Reis‐Filho, Pedram Razavi, Maria E. Arcila, Mark G. Kris, John T. Poirier, Ronglai Shen, Junji Tsurutani, Gary A. Ulaner, Elisa de Stanchina, Neal Rosen, Charles M. Rudin, Maurizio Scaltriti - Cancer Discovery 2020 cited by 289

  21. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention

    Authors: , , , , , , , , , , , , , , , , , , , - Clinical Cancer Research 2018 cited by 578

  22. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2018 cited by 559

  23. Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Barry S. Taylor, Marc Ladanyi, Diana Mandelker, Liying Zhang, Victor E. Reuter, Philip W. Kantoff, David B. Solit, Michael F. Berger, Charles L. Sawyers, Nikolaus Schultz, Howard I. Scher - JCO Precision Oncology 2017 cited by 531

  24. Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martin R. Weiser, Julio García Aguilar, David S. Klimstra, Luis A. Díaz, José Baselga, Liying Zhang, Marc Ladanyi, David M. Hyman, David B. Solit, Mark E. Robson, Barry S. Taylor, Kenneth Offit, Michael F. Berger, Zsofia K. Stadler - Journal of Clinical Oncology 2018 cited by 627